cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Uniqure Nv
6 own
12 watching
Current Price
$21.39
$-0.21
(-0.97%)
logo-qure
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
998.58M
52-Week High
52-Week High
28.255
52-Week Low
52-Week Low
12.52
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
5.0703
iconMarket Capitalization998.58M
icon52-Week High28.255
icon52-Week Low12.52
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio5.0703
What does the Uniqure Nv do?
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More
How much money does Uniqure Nv make?
News & Events about Uniqure Nv.
Globe Newswire
1month ago
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients ...
PR Newswire
1month ago
CSL's Novel Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment CSL's Novel Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Demonstrates Durable...
Globe Newswire
1month ago
~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...
Globe Newswire
6 months ago
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-...
PR Newswire
10 months ago
European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B PR Newswire MARBURG, Germany, March 28...
Frequently Asked Questions
Frequently Asked Questions
What is Uniqure Nv share price today?
plus_minus_icon
Can Indians buy Uniqure Nv shares?
plus_minus_icon
How can I buy Uniqure Nv shares from India?
plus_minus_icon
Can Fractional shares of Uniqure Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Uniqure Nv stocks?
plus_minus_icon
What is today’s traded volume of Uniqure Nv?
plus_minus_icon
What is today’s market capitalisation of Uniqure Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Uniqure Nv?
plus_minus_icon
What percentage is Uniqure Nv down from its 52-Week High?
plus_minus_icon
What percentage is Uniqure Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$21.39
$-0.21
(-0.97%)
logo-qure
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00